1. Canada Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Ondine Biomedical, Inc.

Ondine Biomedical, Inc.

0.22
USD
-0.03
(-12.00%)
-0.09EPS
Mar 03Next Earn
2007 Y
2008 Y
2009 Y
2010 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.03
0.02
0.2
0.2
- -
- -
- -
0.01
0.03
- -
0.01
0.01
0.01
0.06
Basic EPS, GAAP
-0.26
-0.18
-0.9
-0.43
-0.04
-0.09
-0.08
-0.09
-0.68
-0.11
-0.08
-0.08
-0.06
-0.09
Free Cash Flow per Basic Share
-0.24
-0.16
-0.68
-0.38
-0.03
-0.06
-0.04
-0.04
-0.17
-0.09
-0.08
-0.06
-0.05
-0.09
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.19
0.02
0.19
0.03
-0.04
-0.1
-0.15
-0.19
0.17
0.06
0.01
0.02
0.01
-0.2
Tangible Book Value per Share
0.19
0.02
0.1
-0.01
-0.05
-0.11
-0.15
-0.19
0.17
0.06
0.01
0.02
0.01
-0.24
Basic Weighted Avg Shares
51
57
5
8
180
180
180
180
74
180
182
254
465
36
Sales/Revenue/Turnover
2
1
1
2
- -
- -
- -
2
3
1
1
2
3
2
Operating Margin (%)
-823.33
-1,105.73
-464.1
-272.72
-1,401.94
-4,432.17
-3,023.28
-886.15
-681.98
-2,940.91
-1,230.67
-948.95
-1,132.54
-205.78
Depreciation Expense
- -
- -
- -
- -
- -
1
1
1
1
- -
1
1
1
- -
Net Income, GAAP
-13
-10
-5
-3
-6
-17
-14
-16
-50
-19
-14
-19
-30
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-819.34
-1,125.66
-446.06
-212.47
-1,561.65
-4,465.42
-3,014.01
-908.49
-1,949.59
-3,036.36
-1,198
-932.06
-1,115.53
-159.67
Working Capital
10
1
- -
- -
-9
-20
-28
-34
30
11
1
6
2
-2
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
Total Equity
11
1
1
- -
-7
-18
-26
-34
30
12
2
7
3
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-95.89
-168.62
-351.46
-418.34
- -
- -
- -
- -
- -
-93.81
-209.95
-426.2
-569.72
- -

Capital Structure

CAD

•

in mil. unless spec.
Dec'10
Mar'17
Jun'17
ST Debt
1
1
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
9
9
9
Market Capitalization
- -
- -
- -

Working Capital

CAD

•

in mil. unless spec.
Dec'10
Mar'17
Jun'17
Total Current Assets
2
1
2
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
3
4
Payables & Accruals
2
2
2
ST Debt
1
1
3
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-242.48%
-30%
-49.32%
Free Cash Flow
29.83%
36.03%
54.61%
Net Income, GAAP
43.56%
41.59%
54.56%
Sales/Revenue/Turnover
43.29%
31.26%
29.14%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CAD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1
2024
- -
- -
2
2025
- -
- -
3

Semi-annual Earnings Per Share

CAD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.08
2024
- -
- -
-0.08
2025
- -
- -
-0.06

Semi-annual Dividends Per Share

CAD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Carolyn Cross
Full Time Employees
18
Sector
Health technology
Industry
Biotechnology
Address
1100 Melville Street Vancouver BC Canada V6E 4A6
IPO Date
Dec 6, 2021
Website
ondinebio.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Ondine Biomedical Inc. is a biotechnology company specializing in the development and commercialization of therapeutics aimed at improving patient outcomes in critical care, primarily focusing on advanced oxygen biology and inflammation pathways. The company's core product portfolio includes innovative synthetic heme therapies designed to treat acute respiratory distress syndrome (ARDS), severe anemia, and related life-threatening conditions. Ondine's leading product candidates are engineered hemoglobin-based oxygen carriers and heme analogs that enhance oxygen delivery and reduce tissue damage in critically ill patients. These biologic drugs target critical care, surgical, trauma, and emergency medicine segments. Ondine operates predominantly in North America and Europe, leveraging cutting-edge biotechnological research and clinical development expertise. Founded in 2015, the company is headquartered in Toronto, Canada. Ondine collaborates with a range of healthcare providers, research institutions, and strategic partners to accelerate clinical trials and regulatory approvals for its pipeline therapies. In the last 1-2 years, Ondine Biomedical has advanced its clinical development programs significantly, including initiating pivotal Phase 3 clinical trials for its flagship products. The company strengthened its strategic position through new collaborations with key pharmaceutical companies and expanded its operational capabilities to support late-stage development and commercialization efforts. Recent organizational changes have focused on optimizing research and development functions to expedite product pipeline milestones, while exploring potential licensing agreements and market expansion opportunities. No major rebranding or name changes have been reported, while the company remains focused on innovation in critical care therapeutics. Ondine Biomedical's integrated approach encompasses product development, clinical validation, and commercialization readiness in the biopharmaceutical industry.